Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Johnson DH, et al. Among authors: herbst rs. J Clin Oncol. 2004 Jun 1;22(11):2184-91. doi: 10.1200/JCO.2004.11.022. J Clin Oncol. 2004. PMID: 15169807 Clinical Trial.
Emerging therapies in non-small-cell lung cancer.
Khuri FR, Herbst RS, Fossella FV. Khuri FR, et al. Among authors: herbst rs. Ann Oncol. 2001 Jun;12(6):739-44. doi: 10.1023/a:1011197500223. Ann Oncol. 2001. PMID: 11484947 Free article. Review.
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. Komaki R, et al. Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):46-9. doi: 10.1053/srao.2002.31363. Semin Radiat Oncol. 2002. PMID: 11917284 Clinical Trial.
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Herbst RS, et al. J Clin Oncol. 2002 Sep 15;20(18):3815-25. doi: 10.1200/JCO.2002.03.038. J Clin Oncol. 2002. PMID: 12228201 Clinical Trial.
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Herbst RS, et al. J Clin Oncol. 2002 Nov 15;20(22):4440-7. doi: 10.1200/JCO.2002.04.006. J Clin Oncol. 2002. PMID: 12431966 Clinical Trial.
432 results